Kamran Hosseini
Directeur Général chez Surface Ophthalmics, Inc.
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Richard Lindstrom | M | 76 |
Surface Ophthalmics, Inc.
 Surface Ophthalmics, Inc. BiotechnologyHealth Technology Surface Ophthalmics, Inc. operates as a biopharmaceutical company. It focuses on development and commercialization of innovative therapeutics. The firm’s current drug pipeline consists of three proprietary drug candidates. Surface topical eye drop drug candidates, SURF-100 and SURF-200, utilize a patented delivery vehicle. The company is founded by Mark L. Baum and it is headquartered in San Diego, CA. | - |
| Louis C. Drapeau | M | 79 |
Surface Ophthalmics, Inc.
Surface Ophthalmics, Inc. BiotechnologyHealth Technology Surface Ophthalmics, Inc. operates as a biopharmaceutical company. It focuses on development and commercialization of innovative therapeutics. The firm’s current drug pipeline consists of three proprietary drug candidates. Surface topical eye drop drug candidates, SURF-100 and SURF-200, utilize a patented delivery vehicle. The company is founded by Mark L. Baum and it is headquartered in San Diego, CA. | - |
| Mark Baum | M | 51 |
Surface Ophthalmics, Inc.
Surface Ophthalmics, Inc. BiotechnologyHealth Technology Surface Ophthalmics, Inc. operates as a biopharmaceutical company. It focuses on development and commercialization of innovative therapeutics. The firm’s current drug pipeline consists of three proprietary drug candidates. Surface topical eye drop drug candidates, SURF-100 and SURF-200, utilize a patented delivery vehicle. The company is founded by Mark L. Baum and it is headquartered in San Diego, CA. | - |
| Adrienne Graves | M | 69 |
Surface Ophthalmics, Inc.
Surface Ophthalmics, Inc. BiotechnologyHealth Technology Surface Ophthalmics, Inc. operates as a biopharmaceutical company. It focuses on development and commercialization of innovative therapeutics. The firm’s current drug pipeline consists of three proprietary drug candidates. Surface topical eye drop drug candidates, SURF-100 and SURF-200, utilize a patented delivery vehicle. The company is founded by Mark L. Baum and it is headquartered in San Diego, CA. | 6 ans |
| Shelley Thunen | F | 71 |
Surface Ophthalmics, Inc.
Surface Ophthalmics, Inc. BiotechnologyHealth Technology Surface Ophthalmics, Inc. operates as a biopharmaceutical company. It focuses on development and commercialization of innovative therapeutics. The firm’s current drug pipeline consists of three proprietary drug candidates. Surface topical eye drop drug candidates, SURF-100 and SURF-200, utilize a patented delivery vehicle. The company is founded by Mark L. Baum and it is headquartered in San Diego, CA. | 4 ans |
| J. Corley | M | 68 |
Surface Ophthalmics, Inc.
Surface Ophthalmics, Inc. BiotechnologyHealth Technology Surface Ophthalmics, Inc. operates as a biopharmaceutical company. It focuses on development and commercialization of innovative therapeutics. The firm’s current drug pipeline consists of three proprietary drug candidates. Surface topical eye drop drug candidates, SURF-100 and SURF-200, utilize a patented delivery vehicle. The company is founded by Mark L. Baum and it is headquartered in San Diego, CA. | - |
| Perry Sternberg | M | 55 |
Surface Ophthalmics, Inc.
Surface Ophthalmics, Inc. BiotechnologyHealth Technology Surface Ophthalmics, Inc. operates as a biopharmaceutical company. It focuses on development and commercialization of innovative therapeutics. The firm’s current drug pipeline consists of three proprietary drug candidates. Surface topical eye drop drug candidates, SURF-100 and SURF-200, utilize a patented delivery vehicle. The company is founded by Mark L. Baum and it is headquartered in San Diego, CA. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Susan P. Rinne | F | 72 | 11 ans | |
| Ahmed Hamdy | M | 59 | 2 ans | |
| Scott T. Shearer | M | 59 | 8 ans | |
| Kin Hung Yu | M | 61 | 2 ans | |
| Lawrence G. Hamel | M | 72 | 30 ans | |
| Carter J. King | M | 52 | 4 ans | |
| Nacer E. Dean Abrouk | M | - | - | |
| Christopher Kurtz | M | 57 | - | |
| Erik D. Wiberg | M | - | 8 ans | |
| Mark A. Evashenk | M | - | 1 ans | |
| Kimberley Gaumer | F | - | 22 ans | |
| David Abraham | M | 58 | 2 ans |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Etats-Unis | 19 | 100,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Kamran Hosseini
- Réseau Personnel
